Coripharma

Executive Summary

Coripharma is a European pharmaceutical company based in Reykjavik, founded in 2003. The company specializes in generic solid oral dosage forms and offers out-licensing and contract manufacturing services. With an experienced team and solid heritage, Coripharma positions itself as a reliable partner for pharmaceutical companies seeking cost-effective generic solutions. The company's business model focuses on leveraging its manufacturing expertise to serve both in-house product development and external clients. While specific financials and pipeline details are not publicly available, Coripharma's steady presence in the generic drug market suggests a stable but niche operation. Future growth likely depends on securing new licensing agreements and expanding manufacturing capacity. Given the competitive landscape of generic pharmaceuticals, Coripharma's success will hinge on maintaining quality, regulatory compliance, and strategic partnerships.

Upcoming Catalysts (preview)

• TBDNew contract manufacturing agreement50% success
• Q4 2026Expansion of product portfolio via in-licensing30% success
• Q2 2027Regulatory approval for generic product40% success